BRWM
ATRA icon

B. Riley Wealth Management’s Atara Biotherapeutics ATRA Stock Holding History

B. Riley Wealth Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-40
Closed -$52K – 182
2015
Q2 		$52K Sell
40
-80
-67% -$91.8K 0.04% 393
2015
Q1 		$124K Buy
+120
New +$79.3K 0.09% 247

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

B. Riley Wealth Management's ATRA Position: Q3 2015 in Review

B. Riley Wealth Management sold out of Atara Biotherapeutics (ATRA) in Q3 2015, closing a stake of 40 shares — an estimated $52K sold.

B. Riley Wealth Management first reported a position in ATRA in Q1 2015 and held it in 2 quarters. The position peaked at $124K in Q1 2015. 91 funds tracked by Wall St. Rank hold ATRA as of Q3 2015.

  • B. Riley Wealth Management reported no remaining Atara Biotherapeutics position as of Q3 2015 after selling out during the quarter.
  • B. Riley Wealth Management sold 40 Atara Biotherapeutics shares in Q3 2015, an estimated $52K.
  • B. Riley Wealth Management first reported a position in Atara Biotherapeutics in Q1 2015 and held it in 2 quarters.
  • B. Riley Wealth Management's Atara Biotherapeutics position peaked at $124K in Q1 2015.
  • 91 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2015.

Based on B. Riley Wealth Management's 13F filing for Q3 2015, filed 13 Oct 2015.